Available to sourceHuman Prescription DrugOncology & Specialty

ALYFTREK (vanzacaftor, tezacaftor, and deutivacaftor)

125 mg/1 / 50 mg/1 / 10 mg/1 · Film-Coated Tablet

By Vertex Pharmaceuticals Incorporated

NDC: 51167-121
Route: Oral
Therapeutic class: Breast Cancer Resistance Protein Inhibitors [MoA], Chloride Channel Activation Potentiators [MoA], Cystic Fibrosis Transmembrane Conductance Regulator Potentiator , Cytochrome P450 2C9 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA]
Marketing category: NDA

Additional information

Full prescribing information for this product is available on request. Submit a sourcing request and our team will share lot details, dating, and current pricing.

Request this medication

Send a request and we'll respond with availability, lot details, and pricing within 2 business hours.

Related in Oncology & Specialty

See all →

ALYFTREK (vanzacaftor, tezacaftor, and deutivacaftor)

Additional information

Request this medication

Related in Oncology & Specialty

Verzenio (abemaciclib)

Verzenio (abemaciclib)

Verzenio (abemaciclib)

Verzenio (abemaciclib)